Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 12, Issue 5, Pages 499-509Publisher
TAYLOR & FRANCIS AS
DOI: 10.1586/ERM.12.39
Keywords
biomarkers; colorectal cancer; diagnosis; DNA methylation; epigenetic; miRNA; plasma; prediction; prognostication; stool
Categories
Ask authors/readers for more resources
Colorectal cancer (CRC) is a significant health burden worldwide. Despite advancements in treatment options, improvements in CRC patient survival have been limited owing to lack of early detection and limited capacity for optimal therapeutic decision-making. Biomarkers to improve CRC diagnosis, prognosis and prediction of treatment response therefore represent opportunities to improve patient outcome. In addition to genetic alterations and genomic instability, it is now clear that epigenetic alterations play dramatic roles in driving tumor onset and progression in CRC. A recent surge in investigation of epigenetic biomarkers including DNA methylation, miRNA expression and histone modifications has demonstrated that these alterations may be enticing translational biomarker candidates in CRC. In particular, methylation kits have already been incorporated into clinical practice for a handful of cancers, including CRC. This review will aim to summarize the established and emerging roles of epigenetic modifications in CRC detection, prognostication and prediction of treatment response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available